## Gregory R Fulcher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1812164/publications.pdf

Version: 2024-02-01

623734 552781 41 724 14 26 citations g-index h-index papers 43 43 43 1296 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Early protein C activation is reflective of burn injury severity and plays a critical role in inflammatory burden and patient outcomes. Burns, 2022, 48, 91-103.	1.9	1
2	Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial. Cardiovascular Research, 2022, 118, 1103-1114.	3.8	13
3	A co-designed integrated kidney and diabetes model of care improves mortality, glycaemic control and self-care. Nephrology Dialysis Transplantation, 2022, 37, 1472-1481.	0.7	1
4	Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with TypeÂ2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries. Advances in Therapy, 2022, 39, 3735-3748.	2.9	3
5	Continuous subcutaneous insulin infusion alters microRNA expression and glycaemic variability in children with type 1 diabetes. Scientific Reports, 2021, 11, 16656.	3.3	1
6	ARISEâ€"a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design. Endocrine, 2021, 74, 530-537.	2.3	4
7	Epidermal Protein C Levels Correspond to Local Injury Severity and Increased Clinical Support in Burn Patients. European Journal of Burn Care, 2021, 2, 226-237.	0.8	O
8	Amount and Type of Dietary Fat, Postprandial Glycemia, and Insulin Requirements in Type 1 Diabetes: A Randomized Within-Subject Trial. Diabetes Care, 2020, 43, 59-66.	8.6	39
9	Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3638-e3649.	3.6	37
10	Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. Journal of the American Society of Nephrology: JASN, 2020, 31, 2446-2456.	6.1	15
11	Challenges of diabetes management during the <scp>COVID</scp> â€19 pandemic. Medical Journal of Australia, 2020, 213, 56.	1.7	34
12	Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines. Diabetes, Obesity and Metabolism, 2020, 22, 1961-1975.	4.4	11
13	The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: A qualitative study. PLoS ONE, 2019, 14, e0219685.	2.5	11
14	Routine glucose assessment in the emergency department for detecting unrecognised diabetes: a cluster randomised trial. Medical Journal of Australia, 2019, 211, 454-459.	1.7	12
15	Plasma protein C levels are directly associated with better outcomes in patients with severe burns. Burns, 2019, 45, 1659-1672.	1.9	4
16	HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment. BMJ Open, 2019, 9, e033059.	1.9	16
17	Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease. Journal of Diabetes and Its Complications, 2019, 33, 63-68.	2.3	9
18	Suboptimal behaviour and knowledge regarding overnight glycaemia in adults with type 1 diabetes is common. Internal Medicine Journal, 2018, 48, 1080-1086.	0.8	6

#	Article	IF	CITATIONS
19	Utility of the Hospital Admission Risk Programme diabetes risk calculator in identifying patients with type 2 diabetes at risk of unplanned hospital presentations. Internal Medicine Journal, 2018, 48, 1198-1205.	0.8	1
20	Comment on Ooi and Wong. Twin Pregnancy With Gestational Diabetes Mellitus: A Double Whammy? Diabetes Care 2018;41:e15–e16. Diabetes Care, 2018, 41, e67-e67.	8.6	2
21	Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review. Diabetes Research and Clinical Practice, 2018, 140, 118-128.	2.8	71
22	Patient reported barriers are associated with low physical and mental well-being in patients with co-morbid diabetes and chronic kidney disease. Health and Quality of Life Outcomes, 2018, 16, 215.	2.4	5
23	Outcomes for Women with Gestational Diabetes Treated with Metformin: A Retrospective, Case-Control Study. Journal of Clinical Medicine, 2018, 7, 50.	2.4	9
24	Large-for-Gestational-Age Neonates in Type 1 Diabetes and Pregnancy: Contribution of Factors Beyond Hyperglycemia. Diabetes Care, 2018, 41, 1821-1828.	8.6	46
25	Women with type 2 diabetes in pregnancy remain a high-risk group. Minerva Endocrinology, 2018, 43, 224-225.	1.1	1
26	Updated risk factors should be used to predict development of diabetes. Journal of Diabetes and Its Complications, 2017, 31, 859-863.	2.3	5
27	Association Between Glycemic Variability, HbA1c, and Large-for-Gestational-Age Neonates in Women With Type 1 Diabetes. Diabetes Care, 2017, 40, e98-e100.	8.6	18
28	Factors associated with patient activation in an Australian population with comorbid diabetes and chronic kidney disease: a cross-sectional study. BMJ Open, 2017, 7, e017695.	1.9	38
29	Self-management in patients with diabetes and chronic kidney disease is associated with incremental benefit in HRQOL. Journal of Diabetes and Its Complications, 2017, 31, 427-432.	2.3	24
30	Identification of Patients With Diabetes Who Benefit Most From a Health Coaching Program in Chronic Disease Management, Sydney, Australia, 2013. Preventing Chronic Disease, 2017, 14, E21.	3.4	13
31	Evaluation of the performance and outcomes for the first year of a diabetes rapid access clinic. Medical Journal of Australia, 2016, 205, 172-172.	1.7	5
32	Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes. Diabetes Research and Clinical Practice, 2016, 116, 96-99.	2.8	14
33	Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study. BMJ Open, 2016, 6, e008203.	1.9	10
34	Activated protein C to heal pressure ulcers. International Wound Journal, 2016, 13, 986-991.	2.9	14
35	Predictors of Health-Related Quality of Life in Patients with Co-Morbid Diabetes and Chronic Kidney Disease. PLoS ONE, 2016, 11, e0168491.	2.5	33
36	What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres. Diabetes Research and Clinical Practice, 2015, 108, 405-413.	2.8	10

#	Article	IF	CITATIONS
37	Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. Therapeutic Advances in Chronic Disease, 2015, 6, 375-388.	2.5	23
38	Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placeboâ€controlled, doubleâ€blind pilot clinical trial. International Wound Journal, 2015, 12, 422-427.	2.9	22
39	The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: two international surveys. Journal of Medical Economics, 2014, 17, 751-761.	2.1	47
40	Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial. Diabetes Care, 2014, 37, 2084-2090.	8.6	93
41	Prevention of cardiovascular disease: an evidenceâ€based clinical aid. Medical Journal of Australia, 2004, 180, 197-198.	1.7	0